Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: Affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism

Journal of Controlled Release

Volumn 86, Issue 2-3, 2003, Pages 279-292

  Thomsen, Anne Engelbrecht ^a   Friedrichsen, Gerda Marie ^a   Sørensen, Arne Hagsten ^a   Andersen, Rikke ^a   Nielsen, Carsten Uhd ^a   Brodin, Birger ^a   Begtrup, Mikael ^a   Frokjaer, Sven ^a   Steffansen, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acyclovir; Affinity for hPepT1; Dipeptide prodrugs; Stability and in vitro metabolism; Valaciclovir

Indexed keywords

ACICLOVIR; CARRIER PROTEIN; DEXTRO GLUTAMINYL ACYCLOVIR ALANINE; DEXTRO GLUTAMINYL[1 (2 HYDROXYETHYL)THYMINE]ALANINE; ESTER; GLUTAMINYL ACYCLOVIR SARCOMINE; GLUTAMINYL[1 (2 HYDROXYETHYL)THYMINE]SARCOMINE; PEPTIDE TRANSPORTER 1; PRODRUG; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THYMINE DERIVATIVE; UNCLASSIFIED DRUG; VALACICLOVIR;

ACIDITY; ALKALINITY; AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; CATALYST; CELL METABOLISM; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE; NONHUMAN; PH; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; TISSUE HOMOGENATE;

CACO-2 CELLS; CARRIER PROTEINS; HUMANS; PRODRUGS; PURINES; PYRIMIDINES; SOLUTIONS; SYMPORTERS;

EID: 12244302902     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00413-3     Document Type: Article

References (26)

1. de Miranda P., Blum M.R. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12:(Suppl. B):1983;29-37.
2. Beauchamp L.M., Orr G.F., de Miranda P., Burnette T., Krenitsky T.A. Amino acid ester prodrugs of acyclovir. Antivir. Chem. Chemother. 3:(3):1992;157-164.
3. Weller S., Blum M.R., Doucette M., Burnette T., Cederberg D.M., de Miranda P., Smiley M.L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:(6):1993;595-605.
4. Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl etser of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39:(12):1995;2759-2764.
5. de Vrueh R.L.A., Smith P.L., Lee C.-P. Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. J. Pharmacol. Exp. Ther. 286:(3):1998;1166-1170.
6. Han H.-K., Oh D.-M., Amidon G.L. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm. Res. 15:(9):1998;1382-1386.
7. Ganapathy M.E., Huang W., Wang H., Ganapathy V., Leibach F.H. Valacyclovir: a substrate for the intestinal and renal peptide transporter PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246:1998;470-475.
8. Taub M.E., Moss B.A., Steffansen B., Frokjaer S. Influence of oligopeptide transporter binding affinity upon uptake and transport of D-Asp(Obzl)-Ala and Asp(Obzl)-Sar in filter-grown Caco-2 monolayers. Int. J. Pharm. 156:1997;219-228.
9. Nielsen C.U., Andersen R., Brodin B., Frokjaer S., Taub M.E., Steffansen B. Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line. J. Control. Release. 76:(1-2):2001;129-138.
10. Steffansen B., Lepist E.-I., Taub M.E., Larsen B.D., Frokjaer S., Lennernäs H. Stability, metabolism and transport of D-Asp(OBzl)-Ala - a model prodrug with affinity for the oligopeptide transporter. Eur. J. Pharm. Sci. 8:1999;67-73.
11. Lepist E.-I., Kusk T., Larsen D.H., Andersen D., Frokjaer S., Taub M.E., Veski P., Lennernäs H., Friedrichsen G., Steffansen B. Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transport. Eur. J. Pharm. Sci. 11:2000;43-50.
12. Nielsen C.U., Andersen R., Brodin B., Frokjaer S., Steffansen B. Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media. J. Control. Release. 73:(1):2001;21-30.
13. Gi H.-J., Xiang Y., Schinazi R.F., Zhao K. Synthesis of dihydroisoxazole nucleoside and nucleotide analogues. J. Org. Chem. 62:(1):1997;88-92.
14. Pitha J., Ts'o P.O. N-Vinyl derivatives of substituted pyrimidines and purines. J. Org. Chem. 33:(4):1968;1341-1344.
15. Friedrichsen G.M., Nielsen C.U., Steffansen B., Begtrup M. Model prodrugs designed for the intestinal peptide transporter. A synthetic approach for coupling of hydroxy-containing compounds to dipeptides. Eur. J. Pharm. Sci. 14:2001;13-19.
16. Nielsen C.U., Amstrup J., Steffansen B., Frokjaer S., Brodin B. Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line. Am. J. Physiol. Gastrointest. Liver Physiol. 281:2001;G191-199.
17. Krondahl E., Orzechowski A., Ekström G., Lennernäs H. Rat jejunal permeability and metabolism of μ-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharm. Res. 14:(12):1997;1780-1785.
18. Augustijns P., Annaert P., Heylen P., Van den Mooter G., Kinget R. Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. Int. J. Pharm. 166:1998;45-53.
19. Larsen C., Bundgaard H. Kinetics and mechanism of degradation of mecillinam in aqueous solution. Arch. Pharm. Chemi. Sci. 5:1977;66-86.
20. Bailey P.D., Boyd C.A.R., Bronk J.R., Collier I.D., Meredith D., Morgan K.M., Temple C.S. How to make drugs orally active: a substrate template for peptide transporter PepT1. Angew. Chem. Int. Ed. 39:(3):2000;506-508.
21. Brodin B., Nielsen C.U., Steffansen B., Frokjaer S. Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1. Pharmacol. Toxicol. 90:2002;285-296.
22. Gu L., Strickley R.G. Diketopiperazine formation, hydrolysis, and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085. Pharm. Res. 4:(5):1987;392-397.
23. Gu L., Strickley R.G. Preformulation stability studies of the new dipeptide angiotensin-converting enzyme inhibitor RS-10029. Pharm. Res. 5:(12):1988;765-771.
24. Burnette T.C., de Miranda P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab. Dispos. 22:(1):1994;60-64.
25. Burnette T.C., Harrington J.A., Reardon J.E., Merrill B.M., de Miranda P. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J. Biol. Chem. 270:(26):1995;15827-15831.
26. Balimane P.V., Sinko P.J. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm. Drug Dispos. 21:2000;165-174.